EP0465580A1 - Emploi de phosphoglycerides de monoacyle pour ameliorer la penetration de medicaments ophtalmiques dans la cornee - Google Patents

Emploi de phosphoglycerides de monoacyle pour ameliorer la penetration de medicaments ophtalmiques dans la cornee

Info

Publication number
EP0465580A1
EP0465580A1 EP19900906019 EP90906019A EP0465580A1 EP 0465580 A1 EP0465580 A1 EP 0465580A1 EP 19900906019 EP19900906019 EP 19900906019 EP 90906019 A EP90906019 A EP 90906019A EP 0465580 A1 EP0465580 A1 EP 0465580A1
Authority
EP
European Patent Office
Prior art keywords
composition
monoacyl
lysolecithin
phosphoglyceride
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900906019
Other languages
German (de)
English (en)
Other versions
EP0465580A4 (en
Inventor
Tai-Lee Ke
Eugene R. Cooper
Douglas F. Hager
Jamieson Charles Keister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of EP0465580A1 publication Critical patent/EP0465580A1/fr
Publication of EP0465580A4 publication Critical patent/EP0465580A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Definitions

  • the present invention relates to the field of ophthalmic drug delivery. More particularly, this Invention relates to enhancement of the penetration of ophthalmic drugs and other therapeutic agents through the cornea of the eye.
  • the epithelium In order for a drug to pass through the cornea, it must penetrate three layers of tissue, namely, the epithelium, stroma and the endothelium. Except for highly Upophilic drugs, the epithelium is the main barrier to drug penetration of the cornea. Penetration of the stroma basically involves diffusion of the drug through a barrier which Is approximately 360 microns thick. There are currently no known methods of enhancing drug
  • BAC benzalkonium chloride
  • DMSO dimethyl sulfoxide
  • EDTA ethylenedlamine tetraacetate
  • AZONE R 1- dodecylazayl-cycloheptan-2-one
  • a principal objective of the present invention is to provide for a method of enhancing the ability of drugs and therapeutic agents to penetrate the cornea.
  • a further objective of the present Invention is to provide topical ophthalmic compositions containing one or more agents for enhancing the corneal penetration of the active ingredlent(s) contained therein.
  • Figure I compares the amount of a drug, para-aminoclonidine, found in the aqueous humor of rabbits which were administered the drug with and without lysophosphatidylchollne C18:0 (Lysopc).
  • Figure II compares the amount of a drug, para-aminoclonidine, found in the aqueous humor of rabbits which were administered the drug with polyvlnyl alcohol (PVA), with lysopc and PVA and without either lysopc or PVA.
  • PVA polyvlnyl alcohol
  • the present Invention is based on the discovery that amphlpathlc monoacyl phosphoglycerldes effectively and safely enhance the corneal penetration of ophthalmic drugs.
  • These penetration enhancers can be used in compositions comprising any ophthalmic drug which, to be effective, must be substantially taken up by the aqueous humor, ciliary processes and other tissues in the eye upon topical administration. Examples of classes of ophthalmic drugs with which the monoacyl
  • phosphoglycerldes of the present Invention can be used, include: steroids, growth factors, cycloplegics, miotics, mydriatics, therapeutic proteins and peptides, antioxidants, aldose reductase inhibitors, nonsteroidal antiinflammatories, immunomodulators, antiallergies, antimicrobials and anti-glaucoma agents.
  • the penetration enhancing monoacyl phosphoglycerldes used in the present invention have the following structure:
  • R 1 and R 2 is hydrogen, thiol, hydroxyl, amino, lower alkyl, lower alkoxy (eg. methyl, ethyl, methoxy or ethoxy) or alkyl sulflde and the other is an esterlfied, etherifled or amidifled hydrophoblc group, and R 3 is a hydrophllic group.
  • the preferred hydrophoblc groups include saturated and unsaturated aliphatic hydrocarbon groups which range from 14 to 24 carbons in length with zero to 5 double bonds.
  • the aliphatic hydrocarbon groups can be straight or branched chain and may be substituted by one or more aromatic, cycloaliphatic or hydrophilic (e.g.
  • Suitable hydrophllic groups (R 3 ) include 0-inositol, choline, 0-choline, 0-carnltlne, 0-(CH 2 ) 3 -choline, 0-glycerol and 0-lysophosphatidylglycerol.
  • the preferred monoacyl phosphoglycerides are
  • lysophospholipids such as Iysophosphatidyicholine, lysophosphatidylinositol, (lysolecithin), Iysocardiolipin,
  • lysodesoxyliplds lysophosphorylipids and ⁇ -lyso-r-0-alkyl or 0- alkenyl phospholipids such as DL- ⁇ -Lysolecithin-r-0-hexadecyl and DL- ⁇ -Lysolecithin-r-0-alkyl.
  • the most preferred monoacyl phosphoglycerlde is 1-acyl lysophosphatidylcholine (C18:0, C18:1, C16:0 or C16:1).
  • the monoacyl phosphoglycerides which are useful in the present invention may be described as being "amphlpathic", since they include both hydrophilic and hydrophobic groups. While not wishing to be bound by any theory, it is believed that
  • amphipathic monoacyl phosphoglycerldes enhance the corneal penetration of drugs by partition and interaction with protein, glycoprotein and lipld components present in the membrane of the corneal epithelium. Such interaction is believed to alter the degree of order of the proteins and lipids in the membrane, thereby modifying the function of the epithelium as a barrier to drug penetration. Whatever the mechanism, the net result is that drug penetration of the epithelium is enhanced.
  • monoacyl phosphoglycerides in accordance with the present invention to enhance corneal penetration of drugs significantly Increases the amount of drug which is able to penetrate the cornea.
  • the degree of enhancement will vary with different drugs, but in some cases may be as much as 3-fold or more. Because drugs can more effectively penetrate the cornea, less drug is lost due to flow down the punctum and therefore less drug need be administered to effectively treat a particular Indication. This is particularly beneficial when It is necessary to administer drugs which cause severe systemic side effects.
  • the amount of monoacyl phosphoglycerlde required in order to enhance corneal penetration will depend on various factors, such as the solubility, partition coefficient and molecular weight of the ophthalmic drug or therapeutic agent; the exdplents (surfactants, preservatives, polymers) present in the formulation; and the particular monoacyl phosphoglyceride being used. In general, the more lipophilic the drug to be delivered, the less monoacyl phosphoglyceride Is required to enhance penetration, and the higher the concentration of monoacyl phosphoglycerlde, the better the corneal penetration. Typically, one or more monoacyl phosphoglycerides will be used in an amount of from about 0.001% to about 0.5% (weight/volume) preferably from about 0.01 to 0.1%.
  • the monoacyl phosphoglycerldes can be used in any topical drug delivery system wherein an excipient or vehicle will not substantially impair or prevent the monoacyl
  • the monoacyl phosphoglycerldes can be formulated in compositions which are solutions, suspensions, ointments, gels or films.
  • the type of composition will depend on, among other things, the chemical and physical properties of the drug or therapeutic agent to be delivered. These properties are well known to a person of ordinary skill In the art of drug formulation and delivery,
  • the present invention further comprises the use of polymers in conjunction with the monoacyl phosphoglycerides to enhance ocular bioavailability.
  • the compositions of the present invention are retained on the cornea longer. As a result, the penetration enhancing components of the compositions can more effectively interact with the corneal epithelium to enhance penetration of the desired drugs or therapeutic agents Into the eye. It has been found that the use of polymers In conjunction with monoacyl
  • phosphoglycerides can provide for up to about a 9 to 10 fold increase in the amount of drug or therapeutic agent made available to the eye.
  • the effectiveness of the monoacyl phosphoglycerides is improved when the viscosity of the
  • compositions containing the monoacyl phosphoglycerides is increased up to about 1000 centipoise (cps), preferably between about 50 cps. to 300 cps. Polymers are added to provide for this desired viscosity increase.
  • cps centipoise
  • any synthetic or natural polymer which will increase viscosity and is compatible with tissues of the eye and the ingredients of the monoacyl phosphoglycerlde compositions can be used.
  • Such polymers are referred to herein as "viscosity enhancing, ophthalmically acceptable polymers.” Examples include, but are not limited to: natural polysaccharldes and gums, such as: alginates, carrageenan, guar, karaya, locust bean, tragacanth and xanthan; and synthetic polymers, such as:
  • proteins and synthetic polypeptides which enhance viscosity and are ophthalmically acceptable can be used to increase the viscosity of the compositions to provide for better bioavallability.
  • proteins which can be used include: gelatin, collagen, albumin and casein.
  • the preferred viscosity enhancing agents are one or more polymers selected from: PVA, HPMC and HEC.
  • the most preferred agent is HPMC.
  • the viscosity enhancing agents are added to provide for compositions with a viscosity of between about 50 and 300 cps.
  • the preferred method for enhancing the penetration of a drug or therapeutic agent comprises the use of lysophosphatidylcholine (C18:0) at a concentration of about 0.01% to 0.05% in combination with the polymer HPMC in an amount sufficient to provide a composition with a viscosity of about 50 to about 300 cps.
  • compositions which, according to the present invention, comprise monoacyl phosphoglycerldes, the corneal penetration enhancing properties of the monoacyl phosphoglycerides and their use to enhance corneal penetration.
  • composition which can be used to treat glaucoma.
  • the formulation is prepared in two parts.
  • the hydroxypropylmethylcellulose is first dissolved in purified water to make an approximately 10% solution. This solution is then clarified by filtration and sterilized by autoclaving.
  • the mixture is warmed to 40 + 5°C for approximately 30 minutes to complete dissolution of the lysophosphatldylcholine.
  • the pH of the solution is adjusted to 6.5 and the solution is sterilized by sterile filtration.
  • the two solutions are mixed aseptically, stirred, and the remaining purified water is used to bring the solution to final volume.
  • Approximately 85% (8.5 ml) of the batch volume of purified water was added to a container.
  • AH of the ingredients were then added to the container: 0.002g potassium chloride; 0.080g sodium chloride; 0.0021g monobasic potassium phosphate; 0.0216g dibasic sodium phosphate; 0.25g para-aminoclonidine.
  • the ingredients were mixed well.
  • 0.003g lysopc was added to the container and sonnicated with heat (30°C) for 30 minutes.
  • the pH was adjusted to pH 6.0 with IN HCl (0.20 ml).
  • the solution was then filtered through a sterilizing filter Into a sterile receiving vessel.
  • Purified water q.s.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'emploi de phosphoglycérides de monoacyle, améliorant la pénétration de médicaments ophtalmiques appliqués localement, dans l'épithélium cornéen.
EP19900906019 1989-03-29 1990-03-28 Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs Withdrawn EP0465580A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US329924 1988-03-29
US32992489A 1989-03-29 1989-03-29

Publications (2)

Publication Number Publication Date
EP0465580A1 true EP0465580A1 (fr) 1992-01-15
EP0465580A4 EP0465580A4 (en) 1992-03-18

Family

ID=23287604

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900906019 Withdrawn EP0465580A4 (en) 1989-03-29 1990-03-28 Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs

Country Status (7)

Country Link
EP (1) EP0465580A4 (fr)
JP (1) JPH04504258A (fr)
AU (1) AU631204B2 (fr)
CA (1) CA2013225A1 (fr)
IL (1) IL93925A0 (fr)
WO (1) WO1990011079A1 (fr)
ZA (1) ZA902442B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109118A (en) * 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
FR2673513B1 (fr) * 1991-03-05 1993-10-29 Institut Recherche Biologique Sa Nouvelles compositions dietetiques a base de lipides phosphoryles et leur utilisation dans l'amelioration des troubles de la vision.
US6344576B1 (en) 1997-08-18 2002-02-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phospholipid-analogous compounds
PL2574341T3 (pl) 2004-03-29 2017-09-29 University Of South Florida Efektywne leczenie guzów i raka fosforanem tricyrybiny
US8669241B2 (en) * 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
US20210038612A1 (en) * 2018-04-03 2021-02-11 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253472A1 (fr) * 1986-05-16 1988-01-20 Green Cross Corporation Préparation ophtalmologique contenant du flurbiprofen
WO1988009163A1 (fr) * 1987-05-22 1988-12-01 Danbiosyst U.K. Limited Systeme d'administration d'un medicament facilitant sa fixattion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253472A1 (fr) * 1986-05-16 1988-01-20 Green Cross Corporation Préparation ophtalmologique contenant du flurbiprofen
WO1988009163A1 (fr) * 1987-05-22 1988-12-01 Danbiosyst U.K. Limited Systeme d'administration d'un medicament facilitant sa fixattion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9011079A1 *

Also Published As

Publication number Publication date
CA2013225A1 (fr) 1990-09-29
AU631204B2 (en) 1992-11-19
EP0465580A4 (en) 1992-03-18
WO1990011079A1 (fr) 1990-10-04
AU5403090A (en) 1990-10-22
IL93925A0 (en) 1990-12-23
JPH04504258A (ja) 1992-07-30
ZA902442B (en) 1991-01-30

Similar Documents

Publication Publication Date Title
US5221696A (en) Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
US5369095A (en) Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
EP0845268B1 (fr) Utilisation de SCF pour le traitement de la cornée
US5283236A (en) Systemic delivery of polypeptides through the eye
US6630135B1 (en) Use of sustained release antibiotic compositions in ophthalmic surgical procedures
EP1553953B1 (fr) Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome
CA2423354C (fr) Preparations et medications nasales, inhalables et ophtalmiques locales a conservation spontanee
Shen et al. Preparation and ocular pharmacokinetics of ganciclovir liposomes
US20190070176A1 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
US20120264681A1 (en) Buffered ophthalmic compositions and methods of use thereof
KR101560429B1 (ko) 눈의 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물
US20030185892A1 (en) Intraocular delivery compositions and methods
JP2008543877A (ja) Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法
US5278142A (en) Systemic delivery of polypeptides through the eye
Phinney et al. Corneal edema related to accidental Hibiclens exposure
KR20100072333A (ko) 약물 전달을 위한 비히클로서의 비-수성 수혼화성 물질
JPH0723325B2 (ja) 眼病用製剤
AU631204B2 (en) Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
EP0655911B1 (fr) Preparation ophtalmologique
EP0444778A1 (fr) Utilisation d'alkylsaccharides pour augmenter la pénétration de médicaments
JPH03133936A (ja) 蛋白質ゲル状眼用賦形剤
Palmer et al. Tear film, pharmacology of eye drops, and toxicity
RU2434633C2 (ru) Фармацевтические препаративные формы латрункулина
RU2099049C1 (ru) Капли для лечения глазной гипертензии и глаукомы и способ их получения
ES2349699T3 (es) Método y composición que contiene latanoprost para tratar la hipertensión ocular y el glaucoma.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAGER, DOUGLAS, F.

Inventor name: COOPER, EUGENE, R.

Inventor name: KE, TAI-LEE

Inventor name: KEISTER, JAMIESON, CHARLES

A4 Supplementary search report drawn up and despatched

Effective date: 19920127

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930615